A phase II study of ECC4703
Latest Information Update: 30 Nov 2024
Price :
$35 *
At a glance
- Drugs ECC-4703 (Primary)
- Indications Dyslipidaemias; Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- 30 Nov 2024 New trial record
Latest Information Update: 30 Nov 2024